Seeking Alpha

AAIC 2012: Baxter's (BAX +1%) Gammagard immune system therapy for Alzheimer's disease performed...

AAIC 2012: Baxter's (BAX +1%) Gammagard immune system therapy for Alzheimer's disease performed well in Phase 2 trials, with 4 patients who received the most effective dose experiencing a stabilization over 3 years. It's all very small scale, and the proof will come early next year with the results of a larger Phase 3 study, but it's still really encouraging.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|